Status:

COMPLETED

Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals

Lead Sponsor:

Changhai Hospital

Collaborating Sponsors:

National Health and Family Planning Commission, P.R.China

Wu Jieping Medical Foundation

Conditions:

Ischemic Stroke

Large Vessel Occlusion

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Background: Intravenous thrombolysis (IVT) combined with mechanical thrombectomy (MT) has been proven safe and effective in patients with acute ischemic stroke (AIS) of anterior circulation large vess...

Detailed Description

Protocol title: Direct Intra-arterial thrombectomy in order to Revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial...

Eligibility Criteria

Inclusion

  • a clinical diagnosis of acute ischemic stroke,
  • caused by a large vessel occlusion of the anterior circulation (distal intracranial carotid artery or middle M1/proximal M2) cerebral artery confirmed by CTA,
  • CT or MRI ruling out intracranial hemorrhage,
  • eligible for IVT and IAT (within 4.5 hours after symptom onset),
  • a score of at least 2 on the NIH Stroke Scale,
  • age of 18 years or older,
  • written informed consent.

Exclusion

  • \- Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS \>2
  • Any contra-indication for IVT, according to guidelines of the American Heart Association, i.e.:
  • arterial blood pressure exceeding 185/110 mmHg
  • blood glucose less than 2.7 or over 22.2 mmol/L
  • cerebral infarction in the previous 6 weeks with residual neurological deficit or signs of recent infarction on neuro-imaging
  • serious head trauma in the previous 3 months
  • major surgery or serious trauma in the previous 2 weeks
  • gastrointestinal or urinary tract hemorrhage in the previous 3 weeks
  • previous intracerebral hemorrhage
  • use of anticoagulant with INR exceeding 1.7
  • known thrombocyte count less than 100 x 109/L
  • treatment with direct thrombin or factor X inhibitors
  • treatment with heparin (APTT exceeds the upper limit of normal value) in the previous 48 hours.

Key Trial Info

Start Date :

February 21 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 26 2019

Estimated Enrollment :

656 Patients enrolled

Trial Details

Trial ID

NCT03469206

Start Date

February 21 2018

End Date

October 26 2019

Last Update

October 29 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Changhai Hospital

Shanghai, Shanghai Municipality, China, 200433